Predictive Oncology Inc
POAI5.950USD
0.0000.00%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
4.56MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Predictive Oncology Inc Unternehmen
Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Predictive Oncology Inc Informationen
BörsenkürzelPOAI
Name des UnternehmensPredictive Oncology Inc
IPO-datumDec 18, 2009
CEOVennare (Raymond F)
Anzahl der mitarbeiter23
WertpapierartOrdinary Share
GeschäftsjahresendeDec 18
Addresse91 43Rd Street
StadtPITTSBURGH
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl15201
Telefon14124321500
Websitehttps://predictive-oncology.com/
BörsenkürzelPOAI
IPO-datumDec 18, 2009
CEOVennare (Raymond F)
Führungskräfte von Predictive Oncology Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
6.43K
-2373.00%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Shawn P. Matthews
Mr. Shawn P. Matthews
Director
Director
--
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
6.43K
-2373.00%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Feb 8
Aktualisiert: Sun, Feb 8
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Luo (Weiyu)
2.89%
SLN Capital Ltd
1.73%
Diametric Capital
0.15%
The Vanguard Group, Inc.
0.12%
Blacher (Joshua)
0.04%
Andere
95.07%
Aktionäre
Aktionäre
Anteil
Luo (Weiyu)
2.89%
SLN Capital Ltd
1.73%
Diametric Capital
0.15%
The Vanguard Group, Inc.
0.12%
Blacher (Joshua)
0.04%
Andere
95.07%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
3.19%
Corporation
1.73%
Investment Advisor/Hedge Fund
0.15%
Investment Advisor
0.14%
Andere
94.79%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
37
43.21K
0.29%
+14.59K
2025Q3
37
7.39K
0.21%
-26.00K
2025Q2
44
299.51K
2.93%
-288.64K
2025Q1
50
299.35K
3.35%
-293.31K
2024Q4
56
353.94K
4.97%
-213.96K
2024Q3
54
322.08K
5.97%
-246.26K
2024Q2
57
408.73K
8.00%
-114.07K
2024Q1
66
484.20K
11.91%
-86.59K
2023Q4
66
502.45K
12.36%
-67.11K
2023Q3
69
499.46K
12.41%
-50.95K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Luo (Weiyu)
430.05K
2.89%
+430.05K
--
Oct 24, 2025
SLN Capital Ltd
258.03K
1.73%
+258.03K
--
Oct 24, 2025
Diametric Capital
21.81K
0.15%
+21.81K
--
Sep 30, 2025
Blacher (Joshua)
6.47K
0.04%
--
--
Oct 24, 2025
Vennare (Raymond F)
6.43K
0.04%
-2.37K
-26.95%
Nov 28, 2025
Nuzum (Charles Lee Sr)
6.31K
0.04%
--
--
Oct 24, 2025
St Clair (Gregory Sr)
5.73K
0.04%
+1.00
+0.02%
Oct 24, 2025
Chung-Welch (Nancy)
5.60K
0.04%
+4.31K
+334.78%
Sep 09, 2025
Handley (Daniel E)
5.45K
0.04%
--
--
Oct 24, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Sep 25, 2025
Merger
15→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Datum
Ex-Dividendentag
Art
Verhältnis
Sep 25, 2025
Merger
15→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
